Literature DB >> 3223951

Circular-dichroism studies on two murine serum amyloid A proteins.

W D McCubbin1, C M Kay, S Narindrasorasak, R Kisilevsky.   

Abstract

C.d. studies have shown that mouse SAA2 (serum amyloid A2) protein has about one-half of the alpha-helix content of the SAA1 (serum amyloid A1) analogue (15 as against 32%), although secondary-structure prediction analyses based on sequence data do not suggest such a large difference between the forms. The decreased helical content may be a reflection or indication of a stronger propensity to aggregation of the SAA2 form compared with SAA1. The main elements of secondary structure in both proteins are beta-sheets/turns. Interactions with Ca2+ are accompanied by small losses in alpha-helix content, whereas binding to chondroitin-6-sulphate in the presence of millimolar Ca2+ also decreases the amount of secondary structure. However, SAA2 binding to heparan sulphate increases its beta-sheet structure, whereas with SAA1 secondary structure is not apparently altered by its interaction with heparan sulphate. Computer-generated surface profiles show slight differences in accessibility, hydrophilicity and flexibility between the proteins. Understanding these differences may help to explain why SAA2 is found in amyloid fibrils whereas SAA1 is not. In particular, a stronger tendency to aggregation might be the reason why SAA2 is deposited exclusively in these fibrils.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3223951      PMCID: PMC1135483          DOI: 10.1042/bj2560775

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  46 in total

1.  High-density lipoprotein as carrier for amyloid-related protein SAA in rabbit serum.

Authors:  B Skogen; A L Børresen; J B Natvig; K Berg; T E Michaelsen
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

2.  Amyloid A: amphipathic helixes and lipid binding.

Authors:  J P Segrest; H J Pownall; R L Jackson; G G Glenner; P S Pollock
Journal:  Biochemistry       Date:  1976-07-27       Impact factor: 3.162

3.  Surface and inside volumes in globular proteins.

Authors:  J Janin
Journal:  Nature       Date:  1979-02-08       Impact factor: 49.962

4.  Scanning for soft-tissue amyloid.

Authors:  R W Kula; W K Engel; B R Line
Journal:  Lancet       Date:  1977-01-08       Impact factor: 79.321

5.  Snake toxin secondary structure predictions. Structure activity relationships.

Authors:  M J Dufton; R C Hider
Journal:  J Mol Biol       Date:  1977-09-15       Impact factor: 5.469

6.  Isolation and structural properties of murine SAA--the acute phase serum precursor of amyloid AA.

Authors:  J D Sipe; K P McAdam; B F Torain; P S Pollock
Journal:  Immunol Commun       Date:  1977

7.  Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation.

Authors:  K P McAdam; R J Elin; J D Sipe; S M Wolff
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

8.  Amyloid protein SAA is associated with high density lipoprotein from human serum.

Authors:  E P Benditt; N Eriksen
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

9.  Induction of the acute-phase serum protein SAA requires both RNA and protein synthesis.

Authors:  J D Sipe
Journal:  Br J Exp Pathol       Date:  1978-06

10.  Isolation and partial characterization of SAA-an amyloid-related protein from human serum.

Authors:  C J Rosenthal; E C Franklin; B Frangione; J Greenspan
Journal:  J Immunol       Date:  1976-05       Impact factor: 5.422

View more
  41 in total

1.  Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion.

Authors:  Steve Bourgault; James P Solomon; Natàlia Reixach; Jeffery W Kelly
Journal:  Biochemistry       Date:  2011-01-24       Impact factor: 3.162

2.  Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain.

Authors:  M M Verbeek; I Otte-Höller; J van den Born; L P van den Heuvel; G David; P Wesseling; R M de Waal
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Cellular mechanism of fibril formation from serum amyloid A1 protein.

Authors:  Stephanie Claus; Katrin Meinhardt; Tobias Aumüller; Ioana Puscalau-Girtu; Julia Linder; Christian Haupt; Paul Walther; Tatiana Syrovets; Thomas Simmet; Marcus Fändrich
Journal:  EMBO Rep       Date:  2017-06-21       Impact factor: 8.807

Review 4.  Disorder-to-order conformational transitions in protein structure and its relationship to disease.

Authors:  Paola Mendoza-Espinosa; Victor García-González; Abel Moreno; Rolando Castillo; Jaime Mas-Oliva
Journal:  Mol Cell Biochem       Date:  2009-04-09       Impact factor: 3.396

5.  Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice.

Authors:  M S Kindy; D J Rader
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

Review 6.  Anti-amyloid drugs: potential in the treatment of diseases associated with aging.

Authors:  R Kisilevsky
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

7.  Secondary structural features of the bacteriophage Mu-encoded A and B transposition proteins.

Authors:  G Chaconas; W D McCubbin; C M Kay
Journal:  Biochem J       Date:  1989-10-01       Impact factor: 3.857

8.  Short-chain aliphatic polysulfonates inhibit the entry of Plasmodium into red blood cells.

Authors:  Robert Kisilevsky; Ian Crandall; Walter A Szarek; Shridhar Bhat; Christopher Tan; Lee Boudreau; Kevin C Kain
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Adenoviral expression of murine serum amyloid A proteins to study amyloid fibrillogenesis.

Authors:  M S Kindy; A R King; J Yu; C Gerardot; J Whitley; F C de Beer
Journal:  Biochem J       Date:  1998-06-15       Impact factor: 3.857

10.  A computational approach for identifying the chemical factors involved in the glycosaminoglycans-mediated acceleration of amyloid fibril formation.

Authors:  Elodie Monsellier; Matteo Ramazzotti; Niccolò Taddei; Fabrizio Chiti
Journal:  PLoS One       Date:  2010-06-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.